Under development!!!

MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.

  • Cell surface receptors that can activate this pathway via GRB2:

Epidermal Growth Factor Receptor (EGFR; see also Epidermal growth factor). EGFR belongs to Receptor tyrosine kinases, class I.

Trk A/B: High affinity nerve growth factor receptor (TrkA). TrkB tyrosine kinase receptor. See also Neurotrophin.

Fibroblast growth factor receptor

Platelet-derived growth factors and receptors

  • RAF kinase:
  • B-Raf is related to retroviral oncogenes and participates in cellular signal transduction. B-Raf domains include the kinase domain - residues 444-721 and Ras-binding domain - residues 153-237. Mutated B-Raf was found in some human cancers[1]. See more in B-RAF with PLX4032.
  • c-Raf is part of the MAPK pathway. c-Raf domains include the kinase domain - residues 323-618, cysteine-rich domain – residues 136-187 and Ras-binding domain - residues 51-132. Mutations of c-Raf are possible causes of Noonan syndrome[2]. For details on c-Raf see Molecular Playground/C-Raf.

Glycosylated EGFR (PDB code 3i2t)

Drag the structure with the mouse to rotate

ReferencesReferences

  1. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
  2. Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky